



## **PRESS RELEASE**

Stockholm, September 22, 2004

### **ELEKTA CAPITAL™ ESTABLISHED TO PROVIDE FINANCING SOLUTIONS FOR ADVANCED CLINICAL SOLUTIONS**

**Elekta, the international medical technology Group, and global leader in neurosurgery and radiation oncology solutions, today announced the formation of Elekta Capital™. Elekta will work to provide financing to Elekta's North American customers together with De Lage Landen, a Netherlands-based international provider of high-quality asset financing products with a strong presence in healthcare.**

Elekta Capital™ will assist customers in arranging competitive financing for Elekta's leading edge treatment solutions, allowing customers to work with experts who understand the specific needs of the healthcare marketplace as well as the advantages offered by Elekta.

"Elekta has always offered a full range of services to support the entire lifecycle of our treatment solutions," said Anthony De Carolis, President and CEO of Elekta Inc. "This new initiative will simplify the acquisition of Elekta's solutions and improve the competitiveness offered by our proven business model."

"De Lage Landen has a strong, international presence with a thorough understanding of the requirements of medical facilities," De Carolis added. "They are known for their outstanding customer support, which complements our philosophy and approach."

#### **About De Lage Landen:**

De Lage Landen provides flexible asset-based financing products to help manufacturers, vendors and distributors market their capital goods. The company serves its partners in Europe, the Americas, Southeast Asia, Australia and New Zealand. De Lage Landen is a wholly owned subsidiary of the Dutch Rabobank Group that is AAA-rated by Moody's and Standard & Poors. In 2003 De Lage Landen grew its profits to \$ 129.7 million and its balance sheet total to \$ 17.8 billion. For further information, please visit [www.delagelanden.com](http://www.delagelanden.com).

\*\*\*\*\*

#### **For further information, please contact:**

Peter Ejemyr, Group VP Corporate Communications, Elekta AB (publ),  
Phone: +46 733 611 000, e-mail: [peter.ejemyr@elekta.com](mailto:peter.ejemyr@elekta.com)

Elekta is a world-leading supplier of advanced and innovative radiation oncology and neurosurgery solutions and services for precise treatment of cancer and brain disorders. Elekta's solutions are clinically effective, cost efficient and gentle to the patient.

For additional information about Elekta, please visit [www.elekta.com](http://www.elekta.com)